Bazedoxifene

ID: bazedoxifene

Aliases: bazedoxifene acetate, Duavee component, TSE-424, WAY-140424

Type: compound

Route/form: oral

Status: approved_in_combination

Evidence level: approved / labelled

Best data tier: approved label

Support scope: human, review/regulatory

Source types: label, review

Linked sources: 2

Broad outcomes: Hormones / fertility / sexual health

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• estrogen receptor modulator
• ER antagonist in endometrium
• tissue-selective estrogen complex component

Optimization domains

• SERM
• menopause
• osteoporosis
• endocrine

Research basis

• Optimization angle: bazedoxifene is mainly a tissue-selective-estrogen case study, relevant to thinking about bone/endometrium/breast tradeoffs rather than acute performance.
• It is a useful comparison point for estrogen-side-effect theory because it can be paired with estrogen to shape tissue-specific effects.

Limits, risks, and missing evidence

• Label context is menopausal symptom and osteoporosis-prevention care, not male endocrine recovery, PCT, or gynecomastia control.
• Combination estrogen exposure brings its own contraindications and monitoring requirements.

Risk flags

• prescription only
• negative control for pct
• thrombotic risk
• female label context

Linked papers, labels, and reviews

1. DailyMed label: DUAVEE conjugated estrogens/bazedoxifene
   label / dailymed_bazedoxifene_duavee_label
   Approved tissue-selective estrogen complex containing bazedoxifene.
2. Bazedoxifene and the role of third-generation SERMs in postmenopausal osteoporosis
   review / pubmed_bazedoxifene_osteoporosis_review_2012
   Review of bazedoxifene osteoporosis data and SERM risks.